Recombinant Human DR6 (C-6His)

Description

EnkiLife provides the Recombinant Human DR6 (C-6His) protein,aslo know as Tumor Necrosis Factor Receptor Superfamily Member 21,Death Receptor 6,CD358,TNFRSF21,DR6, which features high purity, high activity, and high stability. It can be applied in scientific research, biopharmaceuticals, and other fields.Purity:Greater than 95% as determined by reducing SDS-PAGE;Endotoxin Level:<1 EU/µg as determined by LAL test.;Construction:Recombinant Human Death Receptor 6 is produced by our Mammalian expression system and the target gene encoding Gln42-Leu350 is expressed with a 6His tag at the C-terminus.Accession:O75509. Expression Host:Human Cells.Species:Human.Predicted Molecular Mass:34.62 KDa. Background:Tumor Necrosis Factor Receptor Superfamily Member 21 (TNFRSF21) is a type I transmembrane receptor that includes four extracellular cysteine-rich motifs and a cytoplasmic death domain. DR6 is highly expressed in heart, brain, placenta, pancreas, lymph node, thymus and prostate. DR6 may activate NF-kappa-B and JNK to promote apoptosis and T-cell differentiation. In addition, DR6 binds with N-APP, which is released by the deprivation of Trophic-factor. It triggers caspase activation and degeneration of both neuronal cell bodies (via caspase-3) and axons (via caspase-6). DR6 is also expressed on the tumor cell lines and can be induced by TNF-α.